Figure 4

Association analysis in the patients with IBD who were diagnosed in the prebiologic and biologic eras. (a) The grouped matrix-based visualization combination in patients with UC diagnosed in the prebiologic era. In a balloon plot with antecedent medication groups as columns and consequent drugs as rows, the color represents the aggregated lift in the group and the size shows the aggregated support. The numbers of antecedent medication combinations with the names of the most frequently appeared drugs are displayed as the labels in the columns. The combinations between antecedent groups and a consequent drug with the highest lift value were placed in the upper left of this matrix, and the combinations were placed in the lower right according to the decrease in the lift value. (b) The rank of the top 10 treatment combination in patients with UC diagnosed in the prebiologic era (see description of the plot in Suppl. Figure 5). Each disc indicates the combination between an antecedent medication and a consequent drug with a top 10 high lift value. The support value was 0.0041 and the lift value was 49.0. (c) The grouped matrix-based visualization combination in patients with UC diagnosed in the biologic era. (d) The rank of the top 10 treatment combination in patients with UC diagnosed in the biologic era. The support value was 0.0036 and the lift value was 56.0. (e) The grouped matrix-based visualization combination in patients with CD diagnosed in the prebiologic era. (f) The rank of the top 10 treatment combination in patients with CD diagnosed in the prebiologic era. The disc size indicates the support value (0.0227–0.0455) and the lift value was 10.1. (g) The grouped matrix-based visualization combination in patients with CD diagnosed in the biologic era. (h) The rank of the top 10 treatment combination in patients with CD diagnosed in the biologic era. The support value was 0.0071 and the lift value was 10.1.